Gallery
Picture 1
Alteogen stock forecast some equity strategists in the Alteogen
New with box
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Some equity strategists in the Alteogen stock forecast field stress macroeconomic factors like Korean won stability, which supports export competitiveness. Currency effects could marginally improve Q4 earnings benchmarks. ALTEOGEN, a South Korean biotech firm, is trading at 71.5% below its estimated fair value, indicating potential undervaluation. It's poised for robust growth with earnings expected to increase by 73.06% annually and revenue forecasted to grow at 48.3% per year—both rates surpassing the broader Korean market's growth rates significantly. Despite high volatility in its share price recently and shareholder dilution over the past year, ALTEOGEN demonstrates strong fundamentals with very high projected return on equity and has recently turned profitable. Delve into our full catalog of 178 Asian High Growth Tech and AI Stocks here. Institutional research circling Alteogen stock forecast underscores strategic R&D investments to fend off competitive pressures in biopharma. Earnings projections for FY2024 have been upgraded by 3%, directly impacting target price adjustments.